Marijuana Rescheduling: FDA-Approved Products Moved to Schedule III
Estimated reading time: 3 minutes
In a significant change, the Drug Enforcement Administration (DEA) has issued a new rule to reschedule certain marijuana-based products. This change moves marijuana in FDA-approved products and those under state medical licenses from Schedule I to Schedule III.
The rule is effective as of April 28, 2026. This change means these specified products are now recognized for medical value, aligning with international obligations.
Previously, under the Controlled Substances Act, marijuana was in Schedule I. This classification is for substances with a high potential for abuse and no accepted medical use. Schedule III, however, includes drugs with a moderate to low potential for physical and psychological dependence.
The DEA’s decision follows a recommendation from the Department of Health and Human Services. This decision recognizes marijuana’s lower risk of abuse compared to other Schedule I and II drugs.
This update comes after thorough evaluations. The evaluations considered the frequency of marijuana use and its societal impact. Despite its high usage, marijuana shows fewer severe negative outcomes than some Schedule I and II drugs.
A critical part of the rule is ensuring these products meet U.S. treaty obligations. Import and export of marijuana products still require permits. This maintains the U.S.’s commitment to the Single Convention on Narcotic Drugs.
State medical marijuana licensees will benefit from this rule. They will no longer face certain federal tax penalties, such as the deduction disallowance under Section 280E of the Internal Revenue Code.
The rule also includes an expedited registration process. This process is for entities with state medical marijuana licenses, making it easier to engage in activities like distribution.
This regulatory change provides clarity and aligns U.S. law with current medicinal uses of marijuana. It marks a crucial development in the ongoing dialogue around marijuana’s legal status in the United States.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
